Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesAntineoplastic Agent / Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Tarceva®Application for Approval of Additional Indication of Pancreatic Cancer
Chugai Pharmaceutical Co., 09/21/09
Chugai Pharmaceutical Co., Ltd. announced that the company filed an application with the Japanese Ministry of Health, Labour and Welfare for the approval of an additional indication of pancreatic cancer for the antineoplastic agent / epidermal growth factor receptor tyrosine kinase inhibitor, "TARCEVA Tablet 25 mg and 100 mg" [generic name: erlotinib hydrochloride] (hereafter, Tarceva®).
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09
Dendreon Receives FDA Acknowledgement of Complete Response
Dendreon Coproration, 11/23/09
ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Companys TAP Technology
ImmunoGen, Inc., 11/20/09
Today in Drug/Product Alerts...keeping you current
Receive free subspecialty "5-minute updates" via email
Generic Anticonvulsant Use in Children: Do We Have Evidence to Recommend Brand Formulations?
Archives of Neurology, 11/23/09
Medtronic Receives FDA Warning Letter Following Inspection of Its Mounds View, Minn. Facility
Medtronic, 11/19/09
Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin
Current Medical Research and Opinion, 11/17/09
Sponsor
Article Search
Sponsor